{
  "version": "2025-10-10",
  "payers": [
    {
      "id": "optumrx-like",
      "label": "OptumRx (simulated)",
      "defaultApprovalMonths": 12,
      "globalRules": {
        "prescriberSpecialty": ["rheumatology", "immunology", "internal-medicine-rheum"]
      },
      "drugs": [
        {
          "drugKey": "adalimumab",
          "aliases": ["Humira", "Hyrimoz", "Idacio", "Amjevita", "Hadlima", "Yusimry"],
          "coding": {
            "rxnorm": ["ingredient:Adalimumab"],
            "ndcHint": true
          },
          "indications": ["Rheumatoid arthritis"],
          "initialAuth": {
            "criteria": [
              {
                "id": "dx.ra.severity",
                "type": "diagnosis",
                "field": "diseaseActivity",
                "allowed": ["moderate", "severe"],
                "messageOnFail": "Diagnosis must be moderately to severely active RA."
              },
              {
                "id": "step.dmards",
                "type": "step-therapy",
                "minTriedFailed": 1,
                "allowedClasses": ["csDMARD"],
                "examples": ["methotrexate", "leflunomide", "sulfasalazine"],
                "messageOnFail": "Requires ≥1 trial & failure/contraindication/intolerance of a csDMARD (e.g., methotrexate)."
              },
              {
                "id": "concurrent.immunomod",
                "type": "concurrency",
                "disallowClasses": ["biologic", "JAKi", "targeted-immunomodulator"],
                "messageOnFail": "Cannot be combined with another targeted immunomodulator."
              },
              {
                "id": "labs.screening",
                "type": "documentation",
                "requiredFields": [
                  "tuberculosis_screening_date",
                  "hepatitis_b_screening_date"
                ],
                "messageOnFail": "Provide TB/HBV screening dates (or attest if contraindicated)."
              },
              {
                "id": "prescriber.specialty",
                "type": "prescriber",
                "allowed": ["rheumatology", "immunology", "internal-medicine-rheum"],
                "messageOnFail": "Prescriber should be rheumatology (or in consultation)."
              }
            ],
            "approveIfAllPass": true
          },
          "reauthorization": {
            "criteria": [
              {
                "id": "response.doc",
                "type": "documentation",
                "requiredFields": ["clinical_response_summary"],
                "messageOnFail": "Document positive clinical response (e.g., DAS28/CDAI improvement)."
              },
              {
                "id": "concurrent.immunomod.renew",
                "type": "concurrency",
                "disallowClasses": ["biologic", "JAKi", "targeted-immunomodulator"],
                "messageOnFail": "Do not combine with another targeted immunomodulator."
              }
            ],
            "approveIfAllPass": true
          }
        },
        {
          "drugKey": "abatacept",
          "aliases": ["Orencia"],
          "coding": {
            "rxnorm": ["ingredient:Abatacept"]
          },
          "indications": ["Rheumatoid arthritis"],
          "initialAuth": {
            "criteria": [
              { "ref": "dx.ra.severity" },
              { "ref": "step.dmards" },
              { "ref": "concurrent.immunomod" },
              { "ref": "labs.screening" },
              { "ref": "prescriber.specialty" }
            ],
            "approveIfAllPass": true
          },
          "reauthorization": {
            "criteria": [
              { "ref": "response.doc" },
              { "ref": "concurrent.immunomod.renew" }
            ],
            "approveIfAllPass": true
          }
        },
        {
          "drugKey": "upadacitinib",
          "aliases": ["Rinvoq"],
          "coding": {
            "rxnorm": ["ingredient:Upadacitinib"]
          },
          "indications": ["Rheumatoid arthritis"],
          "initialAuth": {
            "criteria": [
              { "ref": "dx.ra.severity" },
              { "ref": "step.dmards" },
              { "ref": "concurrent.immunomod" },
              {
                "id": "boxed.warning.attestations",
                "type": "documentation",
                "requiredFields": [
                  "cv_risk_discussed",
                  "thrombosis_risk_discussed",
                  "malignancy_risk_discussed"
                ],
                "messageOnFail": "JAK safety attestation required (CV/thrombosis/malignancy)."
              },
              { "ref": "prescriber.specialty" }
            ],
            "approveIfAllPass": true
          },
          "reauthorization": {
            "criteria": [
              { "ref": "response.doc" },
              { "ref": "concurrent.immunomod.renew" }
            ],
            "approveIfAllPass": true
          }
        }
      ],
      "textSnippets": {
        "step.csDMARD.explainer": "Conventional DMARDs include methotrexate, leflunomide, or sulfasalazine. Typically requires ≥3 months trial at maximally tolerated dose.",
        "response.examples": "Positive response may include improved DAS28/CDAI, reduced swollen/tender joints, improved function, or clinician attestation."
      }
    }
  ]
}